HAMZA, S. Et Al. 2022. Tamoxifen suppresses NLRP3 priming via miR-223 in breast cancer independently from Estrogen Receptor alpha. 2d International Conference “Recent Advances in Cancer Research” , (Bern, Switzerland).

HAMZA, S., Garanina, E. E., Khaiboullina, S. F., & TEZCAN, G., (2022). Tamoxifen suppresses NLRP3 priming via miR-223 in breast cancer independently from Estrogen Receptor alpha . 2d International Conference “Recent Advances in Cancer Research”, Bern, Switzerland

HAMZA, SHAIMAA Et Al. "Tamoxifen suppresses NLRP3 priming via miR-223 in breast cancer independently from Estrogen Receptor alpha," 2d International Conference “Recent Advances in Cancer Research”, Bern, Switzerland, 2022

HAMZA, SHAIMAA Et Al. "Tamoxifen suppresses NLRP3 priming via miR-223 in breast cancer independently from Estrogen Receptor alpha." 2d International Conference “Recent Advances in Cancer Research” , Bern, Switzerland, 2022

HAMZA, S. Et Al. (2022) . "Tamoxifen suppresses NLRP3 priming via miR-223 in breast cancer independently from Estrogen Receptor alpha." 2d International Conference “Recent Advances in Cancer Research” , Bern, Switzerland.

@conferencepaper{conferencepaper, author={SHAIMAA HAMZA Et Al. }, title={Tamoxifen suppresses NLRP3 priming via miR-223 in breast cancer independently from Estrogen Receptor alpha}, congress name={2d International Conference “Recent Advances in Cancer Research”}, city={Bern}, country={Switzerland}, year={2022}}